Startseite Kongressberichte 2021 63rd ASH Annual Meeting and Exposition In-Person/Virtual CLL Clinical and Epidemiological I

642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological I

391
Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase 1/2 BRUIN Study

Anthony R. Mato, John M. Pagel, Catherine C. Coombs, et al.

Pirtobrutinib showed promising efficacy in heavily pretreated CLL / SLL (including covalent BTKi, BCL2 inhibitors, BTK C481 mutations). The substance had a broad therapeutic spectrum and was well tolerated. Updated data will be presented in the oral session.

 

392
Preliminary Efficacy and Safety of MK-1026, a Non-Covalent Inhibitor of Wild-Type and C481S Mutated Bruton Tyrosine Kinase, in B-Cell Malignancies: A Phase 2 Dose Expansion Study

Jennifer A. Woyach, Ian W. Flinn, Farrukh T. Awan, et al.

MK-1026 demonstrated promising antitumor activity in a CLL / SLL that had been pretreated many times, including disease progression with previous covalent BTKi treatment. The safety profile turned out to be manageable.

 

393
Three-Year Follow-up of the Ascend Trial: Acalabrutinib Vs Rituximab Plus Idelalisib or Bendamustine in Relapsed/Refractory Chronic Lymphocytic Leukemia

Wojciech Jurczak, Andrzej Pluta, Malgorzata Wach, et al.

Even after 3 years, the effectiveness of Acala monotherapy was sustained while maintaining an acceptable tolerability profile. In patients with R / R-CLL, this follow-up means a significant PFS advantage over standard treatments. No new safety findings were found.

 

394
Retrospective Single-Institution Analysis of Patients with Chronic Lymphocytic Leukemia with TP53 alterations Treated First-Line with Bruton’s Tyrosine Kinase Inhibitor-Based Therapy

Hua-Jay J. Cherng, Raamis Khwaja, Rashmi Kanagal-Shamanna, et al.

The study authors report favorable 4-year PFS and OS rates of 72.7% and 87.2% in patients with TP53-altered CLL with BTKi-based first-line therapy. See abstract for more info.

 

395
A Phase 2 Study Evaluating the Addition of Ublituximab and Umbralisib (U2) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL): A Minimal Residual Disease (MRD)-Driven, Time-Limited Approach

Lindsey E. Roeker, Lori A. Leslie, Jake D. Soumerai, et al.The combination of BTKi, PI3Ki and anti-CD20 monoclonal antibody was well tolerated and effective. A uMRD was achieved in 71 percent of the evaluable patients. This “add-on” approach to continuous ibrutinib treatment induced deep remissions and thus allowed tailor-made, time-limited therapy and sustained treatment-free observation. 

396
SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib versus Bendamustine + Rituximab (BR) in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Constantine S. Tam, Krzysztof Giannopoulos, Wojciech Jurczak, et al.

Zanubrutinib, which was generally well tolerated (with low rates of atrial fibrillation), demonstrated a statistically significant improvement in PFS compared to BR as assessed by the independent review committee (IRC). Superiority was also observed in this registration study with PFS by investigator assessment (INV) and ORR from both IRC and INV. The study authors conclude that their data support the potential utility of zanubrutinib in the frontline management of patients with TN CLL / SLL.